Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension

Next Previous
Trial Profile

Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 8266 (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 15 Mar 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
  • 15 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 11 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top